A New Era in Refractory Neuroblastoma: First-in-Class Triple Therapy Achieves 75% Disease Control in Children
A phase I trial published in JCO demonstrates that a novel combination of MIBG, dinutuximab, and vorinostat achieves up to 75% disease control in relapsed/refractory neuroblastoma, offering new hope for high-risk pediatric patients.